Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a gel replace a chemo drug in eye surgery?

NCT ID NCT07504250

Disease control Sponsor: All India Institute of Medical Sciences, Bhubaneswar Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two treatments used during tear duct surgery for blocked tear ducts: hyaluronic acid gel versus the chemotherapy drug mitomycin-C. The goal is to see if the gel works as well or better at keeping the new tear duct open, with fewer side effects. Thirty-six adults with chronic dacryocystitis will be randomly assigned to one of the two treatments, and their surgical success, complications, and comfort will be tracked for six weeks after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hyaluronic acid (gel) and mitomycin-C (drug)
What this could lead to
If hyaluronic acid works as well as mitomycin-C, it could offer a safer option during tear duct surgery with fewer side effects.
What could go wrong
This is a small, early-phase trial with only 36 participants, so results may not apply widely. Hyaluronic acid might not be as effective as the standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 36 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. All patients within age group 18-65 years diagnosed with chronic dacryocystitis due to Primary Acquired Nasolacrimal Duct Obstruction (PANDO) qualifying for external dacryocystorhinostomy 2. Patients with resolved acute dacryocystitis Exclusion Criteria: 1. Acute dacryocystitis/ Lacrimal sac abscess 2. Secondary NLDO conditions such as infections, inflammatory, traumatic, malignant, etc. 3. Failed/ recurrent/ revision dacryocystorhinostomy and previous dacryocystectomy 4. Presence of systemic diseases affecting wound healing (eg: uncontrolled diabetes, autoimmune conditions, etc.) 5. Use of topical or systemic steroids/ immunosuppressants within 1 month prior to surgery 6. Pregnant or lactating women 7. Known allergy or hypersensitivity to MMC or HA. 8. Inadequate tear volume for biomarker analysis or poor sample quality. 9. Intraoperative flap complications/ excessive bleeding 10. Blood stained discharge or bloody regurgitation 11. Cervical or generalized lymphadenopathy 12. Dry eyes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic dacryocystitis due to primary acquired nasolacrimal duct obstruction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic dacryocystitis dacryocystitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dacryocystitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.